PreviousNextExpandCollapseSearch

Web Page-TreatmentAgent

Treatment Phase Disease Study No. Summary Status Total
Hide details for 111In-ibritumomab tiuxetan111In-ibritumomab tiuxetan
  2
Hide details for Phase IIPhase II
  2
  Leukemia  2011-0393   Dose-Intense Yttrium-90 Ibritumumab Tiuxetan (Zevalin)-Containing Non-Myeloablative Conditioning for Allogeneic Stem Cell Transplantation in B-cell Malignancies  Open  
  Lymphoma  2011-0393   Dose-Intense Yttrium-90 Ibritumumab Tiuxetan (Zevalin)-Containing Non-Myeloablative Conditioning for Allogeneic Stem Cell Transplantation in B-cell Malignancies  Open  
Hide details for 177Lu-DOTA0-Tyr3-Octreotate177Lu-DOTA0-Tyr3-Octreotate
  1
Hide details for Phase IIIPhase III
  1
  Gastrointestinal  2013-0016   A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III study Comparing Treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients with Inoperable, Progressive, Somatostatin Receptor Positive, Midgut Carcinoid Tumours (AAA-III-01).  Open  
Hide details for 18F-PEG6-IPQA18F-PEG6-IPQA
  1
Hide details for Phase IPhase I
  1
  Lung  2009-0832   A phase I study of 18F-PEG6-IPQA as a PET Imaging Agent for Active/Mutant EGFR Expression in Tumors  Open  
Hide details for 2-Chlorodeoxyadenosine2-Chlorodeoxyadenosine
  1
Hide details for Phase IIPhase II
  1
  Leukemia  2004-0223   PHASE II STUDY OF 2-CHLORODEOXYADENOSINE (2CDA) FOLLOWED BY RITUXIMAB IN HAIRY CELL LEUKEMIA  Open  
Hide details for 5-Azacytidine5-Azacytidine
  3
Hide details for Phase I/Phase IIPhase I/Phase II
  3
  Leukemia  2013-0706   A Phase I/II Study of Weekly Schedule Of Brentuximab Vedotin Alone and In Combination With 5-Azacytidine In CD30-Positive Relapsed/Refractory Acute Myeloid Leukemia  Open  
  Leukemia  2013-0141   A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination with 5-azacitidine in Subjects with Myelodysplastic Syndrome who are Naive, Refractory or have Relapsed to 5-azacitidine Therapy  Open  
  Leukemia  2012-1047   Phase I/II Study of the Combination of Quizartinib (AC220) with 5-Azacytidine or Low-Dose Cytarabine for the Treatment of Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)  Open  
Hide details for 5-Fluorouracil5-Fluorouracil
  4
Hide details for Phase I/Phase IIPhase I/Phase II
  1
  Esophagus  2009-0847   Phase I/II Study of Evaluating the Safety and Efficacy of Using a Simultaneous Integrated Boost for Dose Escalation in Patients with Esophageal Cancer  Open  
Hide details for Phase IIPhase II
  2
  Gastrointestinal  2012-0867   A Randomized, Phase II, Placebo-Controlled Study of GDC-0068, an Inhibitor to AKT, in Combination with Fluoropyrimidine plus Oxaliplatin in Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (GO28341)  Open  
  Head And Neck  2007-0433   PHASE II TRIAL OF INDUCTION THERAPY WITH DOCETAXEL, CISPLATIN AND FLUOROURACIL IN PREVIOUSLY UNTREATED PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA AND/OR POORLY DIFFERENTIATED CARCINOMA OF THE NASAL CAVITY AND/OR PARANASAL SINUSES   Open  
Hide details for Phase IIIPhase III
  1
  Esophagus  2011-1036   Phase III Randomized Trial of Proton Beam Therapy versus Intensity-Modulated Radiation Therapy for the treatment of esophageal cancer  Open  
Hide details for 5-FU5-FU
  5
Hide details for Phase IPhase I
  2
  Advanced Cancers  2014-0495   A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, and Pharmacokinetics of AM0010 in Patients with Advanced Solid Tumors  Open  
  Solid Tumors  2013-0346   A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients with Solid Tumors  Open  
PreviousNextExpandCollapseSearch